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Summary
Objectives: Thenumber ofHIV-infected refugeesentering theUSA is increasing. There is little data
describing the HIV-infected refugee population and the challenges encountered when caring for
them. We performed a retrospective case—control analysis of HIV-infected refugees in order to
characterize their co-morbidities, baseline HIV characteristics, and longitudinal care compared to
HIV-infected non-refugees.
Methods: A retrospective chart review was performed of HIV-infected refugees and non-refugees
who were matched for gender, age, and time of establishment of initial HIV care.
Results: The refugee population studied was largely from West Africa. Refugees were more likely
than non-refugees to have heterosexual risk for HIV infection, latent tuberculosis infection, and
active hepatitis B. Refugees were less likely than non-refugees to have a history of substance use,
start antiretrovirals, and be enrolled in a clinical study. The baseline CD4 counts and HIV plasma
viral loads were similar between the two groups.
Conclusions: Clinicians caring for West African HIV-infected refugees should be knowledgeable
about likely co-morbidities and the impact of cultural differences on HIV care. Further studies are
needed to develop culturally competent HIV treatment, education, and prevention programs for
refugees who are beginning a new life in the USA.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 401 793 4397; fax: +1 401 793 4709.
E-mail address: CBeckwith@Lifespan.org (C.G. Beckwith).
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doi:10.1016/j.ijid.2008.06.004Introduction
Prior to 1999, it was difficult for HIV-infected refugees to
enter the USA. The US immigration policy demanded that HIV-
infected refugees prove that their admittance to the USA
would not result in costs to any governmental agency, unlessPublished by Elsevier Ltd. All rights reserved.
HIV infection in refugees 187that agency provided prior consent.1 This policy was revised
by the United States Citizenship and Immigration Services
(USCIS) in 1999 making it no longer necessary for HIV-infected
refugees to prove that they would not be a financial burden to
government-funded programs.2 Since that policy revision,
249 260 refugees gained entrance into the USA between
2000 and 2004, of whom 1085 (0.43%) were HIV-infected
(K.A. Gauger, Department of State, Office of Admissions,
personal communication).
A refugee is an individual who has fled their country of
nationality for fear of persecution. Because refugees have
migrated away from their home country under duress, they
often have experienced difficult living conditions character-
ized by poor nutrition, poverty, overcrowding, and absence
of healthcare infrastructure and immunization programs, and
suffer from physical and psychological trauma. These desta-
bilizing factors have been thought to increase the risk for HIV
infection, which can be magnified by refugees having limited
knowledge of HIV transmission and methods for preven-
tion.3—5 Refugees are also at increased risk of other infectious
and non-infectious co-morbidities including tuberculosis
(TB), parasitic infections, viral hepatitis, and mental health
disorders.3,6 The number of HIV-infected refugees entering
the USA has been increasing since 1999, yet data describing
this population and challenges faced in providing medical
care are sparse. To date, there have been no comparative
studies examining HIV-infected refugees and HIV-infected
non-refugees.
Moreno et al. reviewed their experience in caring for 34
HIV-infected refugees.7 A history of torture was reported in
the majority, and approximately one-half reported a history
of malaria. Other co-morbidities reported included TB, para-
sites, and hepatitis B, and one-half were diagnosed with
major depression and one-third with post-traumatic stress
disorder (PTSD). One-quarter of the refugees studied met the
definition for AIDS and almost one-half met indications for
antiretroviral (ARV) therapy. The authors noted several chal-
lenges in caring for this population including difficulty dis-
cussing the topics of substance abuse, safe sex, and the
indications for antiretroviral treatment.
There is little data on ARV utilization and outcomes for
HIV-infected refugees. However, a study by Moreno et al.
suggested that the refugees who were started on ARV therapy
did well.7 There was a report of a recurrence of PTSD
symptoms after initiation of efavirenz-containing ARV regi-
mens in two refugee patients, which illustrates the unique
challenges that may be encountered in caring for this popu-
lation due to the frequency of mental health disorders.8
We provide comprehensive HIV care for the majority of
HIV-infected refugees resettled in Rhode Island. Our Center is
funded by the Ryan White C.A.R.E. Act, provides HIV care for
approximately 1200 HIV-infected patients in southeastern
New England, and is affiliated with the Alpert Medical School
of Brown University. The overall racial/ethnic composition of
patients receiving care at the center is: 19% Hispanic/Latino,
30% African-American, 48% white, and 19% more than one
race. Women represent 36% and men represent 64% of
patients. Care is provided to all HIV-infected persons referred
to the center, regardless of ability to pay.
The objective of this study was to perform a retrospective
case—control analysis that compared demographic and clin-
ical data from HIV-infected refugees with HIV-infected non-refugees to better characterize the refugee population with
respect to HIV acquisition, disease co-morbidities, HIV stage
upon establishment of care, ARV utilization, enrollment in
clinical studies, and adherence with appointments. The goal
was to provide a better understanding of the unique char-
acteristics of the refugees and the clinical challenges that are
encountered, and to help clinicians who are currently caring
for HIV-infected refugees.
Materials and methods
Fifty-twoHIV-infected persons classified as refugees according
to the United Nations High Commissioner for Refugees, estab-
lished care at our center between 2000 and 2006. Referral to
our center was facilitated by a local refugee resettlement
agency that works in conjunction with the United States
Committee for Refugees and Immigrants. For the purposes
of this study, each refugee was matched with an HIV-infected
non-refugeeof the samegender, using optimal variablematch-
ingonageanddateof their initial appointment.Thedifference
measure usedwas an un-weighted sum of absolute differences
in age and date of initial care. The maximum allowable
difference was three years for age and two years for date of
initial care. SAS macros from the Mayo Clinic Division of
Biostatistics were used to perform the matching.9
The medical charts for these 104 patients (52 refugees, 52
matched non-refugees) were reviewed and the following
variables were extracted and tabulated: demographics (mar-
ital status, country of nationality), primary risk factor for HIV
infection (heterosexual, injection drug use (IDU), men who
have sex with men (MSM), other), substance use (any alcohol
use, IDU), medical co-morbidities (active TB, latent TB infec-
tion (LTBI; defined as a tuberculin skin test 5 mm with a
negative chest X-ray), hepatitis A antibody status, active
hepatitis B (defined as a positive hepatitis B surface antigen),
hepatitis C antibody status, syphilis (rapid plasma regain
(RPR) reactivity), low albumin (defined as albumin <3.0 g/
dl), leukopenia (defined as total white blood cell count
<3.5  109/l), thrombocytopenia (defined as platelet count
<150  109/l), anemia (defined as hemoglobin <12.0 g/dl)),
baseline HIV data [initial CD4 count, initial HIV plasma viral
load (PVL), presence or absence of baseline antiretroviral
resistance determined by genotype testing], and clinical care
data since care was established at the center [initiation of
ARVs, clinical trial enrollment, adherence to scheduled
appointments (defined as the percentage of scheduled
appointments attended), weight change (defined as the
percentage difference in weight between initial weight
and most recent recorded weight), and pregnancies among
female subjects since establishing care].
Odds ratios (OR), 95% confidence intervals (CI), and asso-
ciated p-values for the observed categorical, dichotomous
outcomes (yes/no, positive/negative) were calculated using
McNemar tests. In this context, the OR was interpreted as the
ratio of the odds of a positive response for a refugee to the
odds of a positive response for a non-refugee control condi-
tional on discordance in the covariate between the refugee
and control match. Due to the occasional presence of missing
outcomes, statistical significance was also calculated using
Ekbohm’s method that adjusts for missing covariate values.10
The results from both tests were compared and discussed.
Continuous variables were tested using Wilcoxon signed rank
Table 1 Country of nationality
Region of nationality Refugee n (%) Non-refugee n (%) All participants n (%)
Sub-Saharan Africa 49 (94) 3 (6) 52 (50)
Caribbean 1 (2) 11 (21) 12 (12)
Central America 0 2 (4) 2 (2)
South America 0 4 (7) 4 (4)
USA 0 29 (56) 29 (28)
Other 2 (4) 3 (6) 5 (5)
188 C.G. Beckwith et al.tests, examining whether themedian difference between the
covariate value of the refugee and matched control differed
from zero. Marital status and HIV risk categories were not
dichotomous since there weremore than two outcome levels;
therefore the Fisher’s exact test was used to examine demo-
graphics and risk factors including substance use variables.
All tests were two-sided and p-values0.05 were considered
statistically significant.
The Institutional Review Board of The Miriam Hospital
approved the study protocol.
Results
The medical charts of 52 HIV-infected refugees and 52 HIV-
infected non-refugees matched for age, gender, and date of
initial care were reviewed. Sixty-three percent of the sub-
jects were female. The mean age in the refugee group was
34.2 years (range 21—56 years) and in the non-refugee group
was 35.3 years (range 22—58 years). Between the refugees
and their non-refugee match, the average absolute differ-
ence in age was 1.9 years (range 0—3 years) and the averageTable 2 Summary of demographic characteristics, HIV risk, and su
Refugee n (%) Non-refugee n (%)
Marital status
Divorced 1 (2) 8 (15)
Married 18 (35) 16 (31)
Separated 3 (6) 3 (6)
Single 21 (40) 22 (42)
Widowed 6 (12) 2 (4)
Unknown 3 (6) 1 (2)
Primary HIV risk category
Heterosexual 42 (81) 31 (60)
IDU 1 (2) 6 (12)
MSM 0 (0) 9 (17)
Otherb 5 (10) 3 (6)
Unknown 4 (8) 3 (6)
Alcohol
No 41 (79) 19 (37)
Yes 8 (15) 21 (40)
Unknown 3 (6) 12 (23)
IDU
No 48 (92) 40 (77)
Yes 1 (2) 7 (13)
Unknown 3 (6) 5 (10)
OR, odds ratio; CI, confidence interval; IDU, injection drug use; MSM, m
a OR: the ratio of the odds of a positive response for a non-refugee co
b ‘Other’ includes perinatal transmission and transmission via blood trabsolute difference in date of initiation of HIV care was 92
days (range 0—483 days).
The majority of refugees were from Sub-Saharan Africa
(94%), as demonstrated in Table 1. Sixty-seven percent of the
refugees were from Liberia with 27% from other Sub-Saharan
countries. Interestingly, 44% of the non-refugees were for-
eign born reflecting a diverse patient population at our
center. Demographics, primary risk factor for HIV infection,
and substance use history are summarized in Table 2. There
were no significant differences in marital status with approxi-
mately one-third married in each group. There were signifi-
cant differences in reported primary HIV risk factor
( p = 0.001) among the refugees and non-refugees with 81%
and 60% reporting heterosexual risk, 0% and 17% reporting
male-to-male sex, and 2% and 12% reporting IDU as their
primary risk factor, respectively. Refugees were less likely to
use alcohol than non-refugees (OR 0.18, 95% CI 0.06—0.52,
p < 0.001), with 15% of refugees and 40% of non-refugees
reporting alcohol use. Similarly, the refugees were less likely
to engage in IDU compared to the non-refugees (OR 0.12, 95%
CI 0.003—1.0, p = 0.03), with 2% of refugees and 13% of non-bstance use by refugee status (N = 104)
All n (%) Fisher’s exact test ORa (95% CI) p-Value
0.10
9 (9)
34 (33)
6 (6)
43 (41)
8 (8)
4 (4)
0.001
73 (70)
7 (7)
9 (9)
8 (8)
7 (7)
0.18 (0.06—0.52) <0.001
60 (58)
29 (28)
15 (14)
0.12 (0.003—1.0) 0.03
88 (85)
8 (8)
8 (8)
en who have sex with men.
ntrol to the odds of a positive response for a refugee.
ansfusion or needle stick.
HIV infection in refugees 189refugees reporting IDU. Information regarding risk factor for
HIV infection and substance use was collected from a stan-
dardized questionnaire used by our social worker during the
initial intake session completed on establishment of care at
our center.
Table 3 demonstrates a comparison of co-morbidities
reported or determined by laboratory evaluation at the
initial clinic visit. There were no significant differences in
the number of active TB cases upon initial evaluation with
one case among the refugees and three cases among the non-Table 3 Comparison of co-morbidities between refugees and non-
otherwise noted)
Refugee
n (%)
Non-refugee
n (%)
All n
Active TB
No 49 (94) 46 (88) 95 (9
Yes 1 (2) 3 (6) 4 (4
Unknown 2 (4) 3 (6) 5 (5
Latent TB (N = 98)
Negative 24 (49) 27 (55) 51 (5
Positive 13 (27) 0 (0) 13 (1
Unknown 12 (24) 22 (45) 34 (3
Hepatitis A antibody positive
Negative 6 (12) 29 (56) 35 (3
Positive 42 (81) 20 (38) 62 (6
Unknown 4 (8) 3 (6) 7 (7
Active hepatitis B
Negative 42 (81) 50 (96) 92 (8
Positive 10 (19) 0 (0) 10 (1
Unknown 0 2 (4) 2 (2
Hepatitis C antibody positive
Negative 50 (96) 45 (87) 95 (9
Positive 2 (4) 5 (10) 7 (7
Unknown 0 2 (4) 2 (2
Syphilis (RPR)
Negative 43 (83) 42 (81) 85 (8
Positive 4 (8) 3 (6) 7 (7
Unknown 5 (10) 7 (13) 12 (1
Low albumin
No 46 (88) 46 (88) 92 (8
Yes 6 (12) 5 (10) 11 (1
Unknown 0 1 (2) 1 (1
Leukopenia
No 46 (88) 43 (83) 89 (8
Yes 6 (12) 9 (17) 15 (1
Thrombocytopenia
No 46 (88) 48 (92) 94 (9
Yes 6 (12) 4 (8) 10 (1
Anemia
No 29 (56) 36 (69) 65 (6
Yes 23 (44) 16 (31) 39 (3
OR, odds ratio; CI, confidence interval; N/C, not calculated; NA, not ap
a McNemar test for paired data.
b Adjusted p-value using Ekbohm’s method.
c OR: the ratio of the odds of a positive response for a non-refugee corefugees. Two refugees had a history of active TB prior to
relocation. However, 27% of the refugees had LTBI, as deter-
mined by TB skin testing. There were no cases of LTBI, nor a
history of active TB among the non-refugees (OR infinity, 95%
CI 0.92—infinity, adjusted p < 0.001). The odds of having
hepatitis A antibody reactivity was higher among the refu-
gees (OR 23.0, 95% CI 3.7—947, p < 0.001), with 81% of
refugees having positive antibody tests versus 38% of non-
refugees. Similarly, refugees had a higher odds of having
active hepatitis B (OR infinity, 95% CI 2.2—infinity, adjustedrefugees at initial visit to the immunology clinic (N = 104 unless
(%) Observed data onlya Adjusted for unknownb
ORc (95% CI) p-Value p-Value
0.33 (0.01—4.15) 0.62 0.32
1)
)
)
N/C 0.07 <0.001
2)
3)
5)
23.0 (3.73—947) <0.001 <0.001
4)
0)
)
N/C 0.004 0.002
8)
0)
)
0.2 (0.0—1.79) 0.22 0.20
1)
)
)
2.0 (0.29—22.1) 0.68 0.75
2)
)
2)
1.25 (0.27—6.3) 1.0 0.77
8)
1)
)
0.57 (0.12—2.25) 0.55 NA
6)
4)
1.5 (0.36—7.23) 0.75 NA
0)
0)
1.78 (0.74—4.56) 0.23 NA
2)
8)
plicable; TB, tuberculosis; RPR, rapid plasma reagin.
ntrol to the odds of a positive response for a refugee.
Table 4 Comparison between refugees and non-refugees with respect to baseline CD4 count and plasma viral load
Refugee Non-refugee All p-Valuea
Initial CD4 count, cells/dl (N = 100) 0.51
Median 396 313.5 336.5
Range 20—1252 2—1176 2—1252
Initial plasma viral load (log10) 0.10
Median 4.07 4.32 4.15
Range 1.72—5.70 2.06—5.88 1.72—5.88
a Wilcoxon signed rank test.
190 C.G. Beckwith et al.p = 0.002), with 19% of the refugees and zero non-refugees
having active hepatitis B. Hepatitis C antibody reactivity was
slightly less common among the refugees (4% vs. 10%) but this
was not statistically significant. There were no significant
differences in the following baseline laboratory tests among
refugees and non-refugees, respectively: RPR reactivity (8%,
6%), hypoalbuminemia (12%, 10%), leukopenia (12%, 17%),
thrombocytopenia (12%, 8%), or anemia (44%, 31%).
With respect to baseline HIV clinical variables, the initial
median CD4 count and the initial median HIV PVL among the
refugees (396 cells/dl, 4.07 log10, respectively) and non-
refugees (313.5 cells/dl, 4.32 log10, respectively) were
similar although there was a trend toward higher CD4 counts
and lower PVLs among the refugees (Table 4). Only one
participant, a refugee, had a baseline mutation on genotype
testing that revealed possible antiretroviral resistance
(V108I mutation).
There were differences between the refugees and the
non-refugees in clinical variables after establishing care
(Table 5). Refugees were less likely to initiate ARVs by the
time the study had been completed (OR 0.37, 95% CI 0.13—Table 5 Comparison between refugees and non-refugees with res
unless otherwise noted)
Refugee Non-re
Adherence with scheduled
appointments, % (N = 96)
Median 75% 86%
Range 0.47—1.0 0.38
% Weight change (calculated in lbs)
since entering care
Median 3.8 3.5
Range 10.4—50.5 16.9
HAART use, n (%)
No 23 (44) 11 (2
Yes 29 (56) 41 (7
Clinical study enrollment, n (%)
No 49 (94) 39 (7
Yes 3 (6) 13 (2
Pregnancy, n (%) (N = 68)
No 23 (68) 25 (7
Yes 11 (32) 9 (2
OR, odds ratio; CI, confidence interval; HAART, highly active antiretrovi
a OR: the ratio of the odds of a positive response for a non-refugee co
b Wilcoxon signed rank test.
c McNemar test for paired data.0.92, p = 0.03) with 56% of the refugees and 79% of the non-
refugees starting ARVs. The odds were lower for refugees to
have participated in a clinical study compared to their non-
refugee counterparts (OR 0.17, 95% CI 0.02—0.75, p = 0.02),
with only 6% of the refugees having been enrolled in a clinical
trial compared to 25% of the non-refugees. Refugees were
less likely to adhere to scheduled appointments compared to
non-refugees (median adherence of 75% and 86%, respec-
tively) although this did not reach statistical significance
( p = 0.17). There were no significant differences in percent
weight change since establishing care between the two
groups, with an overall median percent weight increase of
3.7 pounds. Similar proportions of females among the refu-
gees and non-refugees had at least one pregnancy during the
time the study was conducted (32% and 26%, respectively)
which was not statistically different.
Discussion
The HIV-infected refugee population receiving care at our
center is largely from Sub-Saharan Africa with themajority ofpect to clinical characteristics after establishing care (N = 104
fugee All ORa (95% CI) p-Value
0.17b
80%
—1.0 0.38—1.0
0.13b
3.7
—52.3 16.9—52.3
0.37 (0.13—0.92) 0.03c
1) 34 (33)
9) 70 (67)
0.17 (0.02—0.75) 0.02c
5) 88 (85)
5) 16 (15)
1.29 (0.43—4.06) 0.80c
4) 48 (71)
6) 20 (29)
ral therapy.
ntrol to the odds of a positive response for a refugee.
HIV infection in refugees 191refugees coming from Liberia, which is not surprising given
the strong historical ties between Liberia and Rhode Island.
Interestingly, almost one-half of the non-refugees were for-
eign born. Through this analysis, we determined that there
were significant differences between our refugee and non-
refugee populations that are important to consider when
planning refugee HIV care, health education, and prevention
programs.
The majority of refugees and non-refugees reported
heterosexual risk as the primary risk factor for HIV infec-
tion, although the proportion was greater among the refu-
gees. There was almost no reported MSM or IDU HIV risk
among the refugees, which is similar to the findings of other
studies including a recent analysis of HIV-infected African
immigrants in Minnesota.11,12 When developing HIV counsel-
ing, testing, and prevention programs that target refugees
and persons from Sub-Saharan countries, it is important to
realize that heterosexual transmission may be most pre-
valent. Education and counseling should be appropriately
tailored to heterosexual transmission. Refugees may be
offended or react negatively to inquiries of illicit drug
use or of male-to-male sex. Care must be taken to approach
these questions with sensitivity as drug use and homosexu-
ality often are not discussed openly in many cultures.
Providers should complete HIV risk assessment and HIV
prevention education in a manner that is culturally accep-
table to the refugee population.
There were a number of differences with respect to co-
morbidities. LTBI and active hepatitis B infection were more
common among the refugees. Providers caring for refugees
need to have the resources and expertise to treat LTBI and
active hepatitis B or have the capacity to refer for appro-
priate treatment. There is an increased risk of LTBI convert-
ing to active TB in persons who are HIV-infected, therefore
completion of LTBI treatment is important and referral to a
dedicated TB clinic should be considered if available. There
was not a significant difference in hepatitis C antibody
reactivity among the refugees and non-refugees, which
can likely be accounted for by the low number of subjects
reporting IDU as their primary risk factor. There was not a
significant difference in RPR reactivity and we were not able
to successfully compare the presence of other sexually
transmitted infections due to lack of data on a significant
proportion of subjects. We found no differences in baseline
albumin or hematological abnormalities.
The refugees and non-refugees had similar stages of HIV
disease upon presentation. Median CD4 counts and PVLs
were similar and there was essentially no baseline HIV
resistance on genotype testing among either group. How-
ever, a smaller proportion of refugees were started on ARVs
during the course of the study compared to non-refugees
(56% and 79%, respectively). There were several possible
reasons for this. In our experience, explaining the indica-
tions for ARV treatment and reasons for initiating or post-
poning ARV therapy to refugees can be challenging. Refugees
may not understand why a provider would not begin treat-
ment (based upon a preserved CD4 count) if treatment is
effective. The perception that treatment is being withheld
can lead to feelings of mistrust. In other instances, refugees
who are asymptomatic may feel as though they do not
require medicine and may be reluctant to start treatment.
Refugees may have only experienced taking medicine whenill, not for the prevention of illness, including opportunistic
infections.
Issues surrounding HIV treatment can be difficult to effec-
tively communicate. Success often requires multiple expla-
nations provided over several visits that occur with the aid of
translators and cultural interpreters. The medical experi-
ences of refugees and their perception of healthcare are
predictably dissimilar from those of the provider, and cultural
differences play an important role. For many refugees,
healthcare experiences may be limited to interactions with
traditional healers only. Challenges in communication sur-
rounding the use of ARVs likely contributed to fewer refugees
initiating HIV treatment during the course of this study
compared to non-refugees. At our center, ARV therapy is
available to all patients through the Rhode Island AIDS Drug
Assistance Program, so access to medication cannot account
for this difference.
Refugees were less likely to enroll in a clinical study
compared to non-refugees. Clinical studies included trials
conducted by the AIDS Clinical Trials Group. There were no
studies being conducted during this time that excluded
enrollment of refugees based on their refugee status alone.
Enrollment in clinical studies was not possible if the patient
could not speak English or Spanish, which may have influ-
enced our findings. However, many of the Liberian refugees
were English speaking and approximately one-half of the
non-refugees were foreign born, so this limitation likely did
not account for the entire difference observed.We hypothe-
size that decreased enrollment among the refugees can be
attributed to factors that similarly led to decreased utiliza-
tion of ARVs. Effectively communicating the objectives of a
clinical study to a refugee was challenging given cultural
differences, and refugees often had a limited understanding
of, or fear of, human research. In addition, enrollment
would have required the refugee to disclose their HIV-posi-
tive status to additional healthcare workers and refugees
often tried to avoid disclosurewhenever possible. Strategies
to increase enrollment of refugees into clinical studies need
to be developed.
The proportion of refugees and non-refugees who became
pregnant since care was established was similar (32% and
26%, respectively), which was surprising since there was a
perception that more pregnancies occurred among refugee
patients. This perception was likely a consequence of preg-
nancies occurring within different contexts between refu-
gees and non-refugees. Refugee pregnancies often occurred
in the absence of pre-pregnancy planning, while non-refugee
pregnancies were typically planned in conjunction with the
HIV provider and with the use of antiretroviral therapy.
Unplanned pregnancies among refugees created the need
for urgent clinical evaluations, initiation of ARVs, and social
work assistance thus creating a sense of ‘crisis management’
among the providers. Pregnancies among HIV-infected refu-
gees deserves further research including examination of
motivations to become pregnant, circumstances that lead
to pregnancy such as inability to negotiate condom usage
with sexual partners, pre-natal care, use of ARVs, and preg-
nancy outcomes.
There were limitations to this study. Data collection was
retrospective and limited to a medical chart review only. Our
refugee population was homogeneous with the majority of
refugees coming from Liberia and other Sub-Saharan coun-
192 C.G. Beckwith et al.tries, therefore, these results may not apply to other HIV-
infected refugee populations. Refugees from Asia and East-
ern Europe, for instance, may have different co-morbidities
and challenges since HIV transmission in these parts of the
world is predominantly through injection drug use. Further
investigation into mental health disorders and pregnancy
among refugees and non-refugees was not possible given
the limitations of the study design.
The HIV-infected refugee population in the USA will
continue to grow and the unique needs of this population
require attention. Further investigation is needed in the
following areas: HIV treatment outcomes among refugees,
HIV diversity and the subsequent impact on treatment and
the emergence of ARV resistance, investigation into social
and cultural factors that predict successful engagement in
longitudinal HIV care, preferred ARV regimens and issues of
ARV adherence and toxicity, issues surrounding pregnancy
and pregnancy outcomes, and further investigation into co-
morbidities with particular attention to mental health dis-
orders. Further research will help create multidisciplinary
comprehensive care programs that are capable of deliver-
ing high-quality care to this disenfranchised and vulnerable
population.
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